ATOS · Atossa Therapeutics, Inc. · Executive Compensation
$1.65
-0.10 (-5.71%)
At close · Nov 20
Return incl. dividend (before tax)
Q2 2023 earnings call transcript
Going-concern doubt
— flagged Nov 10, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Substantial doubt exists about our ability to continue as a going concern.”View the 10-Q filed Nov 10, 2026
Market Cap
$15.92M
Shares
9.98M
Volume · Nov 20
48.93K
Avg daily vol (3M)
67.59K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Steven Quay | M.D., Ph. D. Chief Executive Officer | $2,502,856 |
| Heather Rees | CPA (Inactive) | $981,724 |
| Mark J. Daniel | — | $536,489 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Steven Quay | M.D., Ph. D. Executive Officer | $2,764,082 |
| Heather Rees | CPA (inactive) | $1,149,674 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Greg Weaver | — | $2,379,426 |
| Steven Quay | M.D., Ph. D. Executive Officer | $2,356,220 |
| Kyle Guse | General Counsel and Secretary | $1,171,631 |
| Heather Rees | CPA (inactive) | $687,463 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Steven Quay | M.D. Ph. D. Executive Officer | $3,160,876 |
| Kyle Guse | General Counsel and Secretary | $1,527,871 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Steven Quay | MD., Ph.D. Executive Officer | $5,892,563 |
| Kyle Guse | General Counsel and Secretary | $2,801,628 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Steven Quay | MD., Ph.D. Executive Officer | $2,936,284 |
| Kyle Guse | General Counsel and Secretary | $1,385,466 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Steven Quay | MD., Ph.D. President and Chief Executive Officer | $5,807,923 |
| Kyle Guse | Chief Financial Officer, General Counsel and Secretary | $2,329,472 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Steven Quay | MD., Ph.D. President and Chief Executive Officer | $2,172,344 |
| Kyle Guse | Chief Financial Officer, General Counsel and Secretary | $1,088,931 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Mark Daniel | principal accounting officer | Appointed | 2025-10-14 |
| Mark Daniel | Chief Financial Officer | Appointed | 2025-10-14 |
| Heather Rees | Chief Financial Officer | Appointed | 2024-07-02 |
| Dr. Tessa Cigler, M.D., M.P.H. | Class II director | Appointed | 2024-03-12 |
| Jonathan Finn | Class I director | Appointed | 2023-11-09 |
|
Greg Weaver
“Mr. Weaver tendered his resignation to pursue other opportunities and not due to any disagreement with the Company.”
|
member of the Board of Directors | Resigned | 2023-10-06 |
|
Greg Weaver
“Mr. Weaver tendered his resignation to pursue other opportunities and not due to any disagreement with the Company.”
|
Executive Vice President and Chief Financial Officer | Resigned | 2023-10-06 |
| Greg Weaver | Executive Vice President and Chief Financial Officer | Appointed | 2023-06-01 |
Leadership
- Steven Quay CEO
- Greg Weaver CFO
- Mark Daniel CFO, Chief Accounting Officer
- Mark J. Daniel CFO
- Dr. Tessa Cigler, M.D., M.P.H. Board Member
- H. Lawrence Remmel, Esq. Board Member
- Jonathan Finn Board Member
- Jonathan Finn, CFA Board Member
- Shu-Chih Chen Board Member
Key facts
CIK
1488039
CUSIP
04962H704
13F (30d)
61 filings
35 filers
Visit website
Investor relations